Ischaemiás szívbetegség és tumoros betegségek együttes elofordulása: Kérdések és problémák

Translated title of the contribution: Ischaemic heart disease in cancer patients: Questions and problems

Gulácsi Bárdos Petra, Szokol Miklós, Lódi Mária, Czuriga Dániel, I. Czuriga, I. Édes, Nagy András Csaba, Sármán Balázs

Research output: Contribution to journalReview article

Abstract

Cardiovascular and oncologic diseases are the causes of more than 50 percent of mortality in Europe. In 2015 oncologic and cardiovascular mortality reached 70 percent in Hungary. Patients who receive anticancer therapies are at a 2- to 7-fold greater long-term risk of acute coronary syndrome; also concomittant oncologic diseases further increase the mortality of myocardial infarction. Unfortunately there is not enough data concerning cardiovascular treatment of oncologic patients because they were excluded from most of the studies and registries. Because there is no clear protocol to treat such patients, only small studies and personal experiences could guide our medical therapies. The role of cardio-oncology is even more important, because due to the new treatments the number of tumor survivors rapidly increases. In the US more than 20 millions survivals are expected by 2025 who were treated by any kind of malignant tumors. It is not surprising that in 2014 the American Society of Cardiology declared cardio-oncology as a special and important field in cardiology, and in 2016 European Society of Cardiology released the first cardio-oncologic guideline. In this review we summarize questions and problems concerning the treatment of oncologic patient with ischaemic heart disease based on resent guidelines, published studies and local protocols.

Original languagePolish
Pages (from-to)1691-1697
Number of pages7
JournalOrvosi Hetilap
Volume158
Issue number43
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

Myocardial Ischemia
Neoplasms
Cardiology
Mortality
Guidelines
Therapeutics
Hungary
Acute Coronary Syndrome
Survivors
Registries
Cardiovascular Diseases
Myocardial Infarction
Survival

Keywords

  • Antineoplastic agents
  • Cardiotoxicity
  • Cardiovascular disease
  • Neoplasms
  • Thrombosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ischaemiás szívbetegség és tumoros betegségek együttes elofordulása : Kérdések és problémák. / Petra, Gulácsi Bárdos; Miklós, Szokol; Mária, Lódi; Dániel, Czuriga; Czuriga, I.; Édes, I.; Csaba, Nagy András; Balázs, Sármán.

In: Orvosi Hetilap, Vol. 158, No. 43, 01.10.2017, p. 1691-1697.

Research output: Contribution to journalReview article

Petra, Gulácsi Bárdos ; Miklós, Szokol ; Mária, Lódi ; Dániel, Czuriga ; Czuriga, I. ; Édes, I. ; Csaba, Nagy András ; Balázs, Sármán. / Ischaemiás szívbetegség és tumoros betegségek együttes elofordulása : Kérdések és problémák. In: Orvosi Hetilap. 2017 ; Vol. 158, No. 43. pp. 1691-1697.
@article{ff517a4c7e584b29be5e8e4dade172cd,
title = "Ischaemi{\'a}s sz{\'i}vbetegs{\'e}g {\'e}s tumoros betegs{\'e}gek egy{\"u}ttes elofordul{\'a}sa: K{\'e}rd{\'e}sek {\'e}s probl{\'e}m{\'a}k",
abstract = "Cardiovascular and oncologic diseases are the causes of more than 50 percent of mortality in Europe. In 2015 oncologic and cardiovascular mortality reached 70 percent in Hungary. Patients who receive anticancer therapies are at a 2- to 7-fold greater long-term risk of acute coronary syndrome; also concomittant oncologic diseases further increase the mortality of myocardial infarction. Unfortunately there is not enough data concerning cardiovascular treatment of oncologic patients because they were excluded from most of the studies and registries. Because there is no clear protocol to treat such patients, only small studies and personal experiences could guide our medical therapies. The role of cardio-oncology is even more important, because due to the new treatments the number of tumor survivors rapidly increases. In the US more than 20 millions survivals are expected by 2025 who were treated by any kind of malignant tumors. It is not surprising that in 2014 the American Society of Cardiology declared cardio-oncology as a special and important field in cardiology, and in 2016 European Society of Cardiology released the first cardio-oncologic guideline. In this review we summarize questions and problems concerning the treatment of oncologic patient with ischaemic heart disease based on resent guidelines, published studies and local protocols.",
keywords = "Antineoplastic agents, Cardiotoxicity, Cardiovascular disease, Neoplasms, Thrombosis",
author = "Petra, {Gul{\'a}csi B{\'a}rdos} and Szokol Mikl{\'o}s and L{\'o}di M{\'a}ria and Czuriga D{\'a}niel and I. Czuriga and I. {\'E}des and Csaba, {Nagy Andr{\'a}s} and S{\'a}rm{\'a}n Bal{\'a}zs",
year = "2017",
month = "10",
day = "1",
doi = "10.1556/650.2017.30897",
language = "Polish",
volume = "158",
pages = "1691--1697",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "43",

}

TY - JOUR

T1 - Ischaemiás szívbetegség és tumoros betegségek együttes elofordulása

T2 - Kérdések és problémák

AU - Petra, Gulácsi Bárdos

AU - Miklós, Szokol

AU - Mária, Lódi

AU - Dániel, Czuriga

AU - Czuriga, I.

AU - Édes, I.

AU - Csaba, Nagy András

AU - Balázs, Sármán

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Cardiovascular and oncologic diseases are the causes of more than 50 percent of mortality in Europe. In 2015 oncologic and cardiovascular mortality reached 70 percent in Hungary. Patients who receive anticancer therapies are at a 2- to 7-fold greater long-term risk of acute coronary syndrome; also concomittant oncologic diseases further increase the mortality of myocardial infarction. Unfortunately there is not enough data concerning cardiovascular treatment of oncologic patients because they were excluded from most of the studies and registries. Because there is no clear protocol to treat such patients, only small studies and personal experiences could guide our medical therapies. The role of cardio-oncology is even more important, because due to the new treatments the number of tumor survivors rapidly increases. In the US more than 20 millions survivals are expected by 2025 who were treated by any kind of malignant tumors. It is not surprising that in 2014 the American Society of Cardiology declared cardio-oncology as a special and important field in cardiology, and in 2016 European Society of Cardiology released the first cardio-oncologic guideline. In this review we summarize questions and problems concerning the treatment of oncologic patient with ischaemic heart disease based on resent guidelines, published studies and local protocols.

AB - Cardiovascular and oncologic diseases are the causes of more than 50 percent of mortality in Europe. In 2015 oncologic and cardiovascular mortality reached 70 percent in Hungary. Patients who receive anticancer therapies are at a 2- to 7-fold greater long-term risk of acute coronary syndrome; also concomittant oncologic diseases further increase the mortality of myocardial infarction. Unfortunately there is not enough data concerning cardiovascular treatment of oncologic patients because they were excluded from most of the studies and registries. Because there is no clear protocol to treat such patients, only small studies and personal experiences could guide our medical therapies. The role of cardio-oncology is even more important, because due to the new treatments the number of tumor survivors rapidly increases. In the US more than 20 millions survivals are expected by 2025 who were treated by any kind of malignant tumors. It is not surprising that in 2014 the American Society of Cardiology declared cardio-oncology as a special and important field in cardiology, and in 2016 European Society of Cardiology released the first cardio-oncologic guideline. In this review we summarize questions and problems concerning the treatment of oncologic patient with ischaemic heart disease based on resent guidelines, published studies and local protocols.

KW - Antineoplastic agents

KW - Cardiotoxicity

KW - Cardiovascular disease

KW - Neoplasms

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85032440031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032440031&partnerID=8YFLogxK

U2 - 10.1556/650.2017.30897

DO - 10.1556/650.2017.30897

M3 - Review article

C2 - 29135296

AN - SCOPUS:85032440031

VL - 158

SP - 1691

EP - 1697

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 43

ER -